Cargando…
COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial
The SARS-CoV-2 pandemic had a devastating impact on the world’s population in the years 2020–2022. The rapid development of vaccines enabled a reduction in the mortality and morbidity of COVID-19, but there are limited data about their effects on immunocompromised children. The aim of this prospecti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866698/ https://www.ncbi.nlm.nih.gov/pubmed/36680039 http://dx.doi.org/10.3390/vaccines11010195 |
_version_ | 1784876156413018112 |
---|---|
author | Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Ludwikowska, Kamila Szenborn, Filip Moskwa, Natalia Kurek, Katarzyna Kałwak, Krzysztof Szenborn, Leszek Ussowicz, Marek |
author_facet | Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Ludwikowska, Kamila Szenborn, Filip Moskwa, Natalia Kurek, Katarzyna Kałwak, Krzysztof Szenborn, Leszek Ussowicz, Marek |
author_sort | Matkowska-Kocjan, Agnieszka |
collection | PubMed |
description | The SARS-CoV-2 pandemic had a devastating impact on the world’s population in the years 2020–2022. The rapid development of vaccines enabled a reduction in the mortality and morbidity of COVID-19, but there are limited data about their effects on immunocompromised children. The aim of this prospective study was to evaluate the safety and efficacy of the mRNA BNT162b2 (Pfizer/Biontech) vaccine in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Material and methods: Two cohorts of 34 children after allo-HSCT and 35 healthy children aged 5–11 years were vaccinated with two doses of the mRNA BNT162b2 (10 µg) vaccine. All children were evaluated for adverse effects with electronic surveys and the immunogenicity of the vaccine was assessed with anti-SARS-CoV-2 IgG titer measurements. Results: All reported adverse events (AEs) were classified as mild. The most common AE was pain at the injection site. All the other AEs (both local and systemic) were rarely reported (<15% patients). Both groups showed a similar response in anti-SARS-CoV-2 IgG production. Patients after allo-HSCT that were undergoing immunosuppressive treatment presented a poorer immunological response than patients off of treatment. Time since HSCT, patient age, lymphocyte count, and total IgG concentration did not correlate with initial/post-vaccination anti-SARS-CoV-2 IgG titers. Most patients who were eligible for a third dose of the vaccine had an excellent humoral response observed after two vaccine doses. Conclusions: The COVID-19 mRNA BNT162b2 vaccine is very well tolerated and highly immunogenic in 5–11-year-old children after HSCT. Children >2 years of age after HSCT who did not receive immunosuppressive treatment presented excellent antibody production after two doses of the vaccine, but children on immunosuppression may require a more intense vaccination schedule. |
format | Online Article Text |
id | pubmed-9866698 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98666982023-01-22 COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Ludwikowska, Kamila Szenborn, Filip Moskwa, Natalia Kurek, Katarzyna Kałwak, Krzysztof Szenborn, Leszek Ussowicz, Marek Vaccines (Basel) Article The SARS-CoV-2 pandemic had a devastating impact on the world’s population in the years 2020–2022. The rapid development of vaccines enabled a reduction in the mortality and morbidity of COVID-19, but there are limited data about their effects on immunocompromised children. The aim of this prospective study was to evaluate the safety and efficacy of the mRNA BNT162b2 (Pfizer/Biontech) vaccine in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. Material and methods: Two cohorts of 34 children after allo-HSCT and 35 healthy children aged 5–11 years were vaccinated with two doses of the mRNA BNT162b2 (10 µg) vaccine. All children were evaluated for adverse effects with electronic surveys and the immunogenicity of the vaccine was assessed with anti-SARS-CoV-2 IgG titer measurements. Results: All reported adverse events (AEs) were classified as mild. The most common AE was pain at the injection site. All the other AEs (both local and systemic) were rarely reported (<15% patients). Both groups showed a similar response in anti-SARS-CoV-2 IgG production. Patients after allo-HSCT that were undergoing immunosuppressive treatment presented a poorer immunological response than patients off of treatment. Time since HSCT, patient age, lymphocyte count, and total IgG concentration did not correlate with initial/post-vaccination anti-SARS-CoV-2 IgG titers. Most patients who were eligible for a third dose of the vaccine had an excellent humoral response observed after two vaccine doses. Conclusions: The COVID-19 mRNA BNT162b2 vaccine is very well tolerated and highly immunogenic in 5–11-year-old children after HSCT. Children >2 years of age after HSCT who did not receive immunosuppressive treatment presented excellent antibody production after two doses of the vaccine, but children on immunosuppression may require a more intense vaccination schedule. MDPI 2023-01-16 /pmc/articles/PMC9866698/ /pubmed/36680039 http://dx.doi.org/10.3390/vaccines11010195 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Matkowska-Kocjan, Agnieszka Owoc-Lempach, Joanna Ludwikowska, Kamila Szenborn, Filip Moskwa, Natalia Kurek, Katarzyna Kałwak, Krzysztof Szenborn, Leszek Ussowicz, Marek COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title | COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title_full | COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title_fullStr | COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title_full_unstemmed | COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title_short | COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5–11 Years Old–Non-Randomized Clinical Trial |
title_sort | covid-19 mrna vaccine tolerance and immunogenicity in hematopoietic stem cell transplantation recipients aged 5–11 years old–non-randomized clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866698/ https://www.ncbi.nlm.nih.gov/pubmed/36680039 http://dx.doi.org/10.3390/vaccines11010195 |
work_keys_str_mv | AT matkowskakocjanagnieszka covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT owoclempachjoanna covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT ludwikowskakamila covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT szenbornfilip covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT moskwanatalia covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT kurekkatarzyna covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT kałwakkrzysztof covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT szenbornleszek covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial AT ussowiczmarek covid19mrnavaccinetoleranceandimmunogenicityinhematopoieticstemcelltransplantationrecipientsaged511yearsoldnonrandomizedclinicaltrial |